All Stories

  1. Efficacy of 3-day versus 5-day aprepitant regimens for long-delayed chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy

    Article • Expert Opinion on Pharmacotherapy, November 2023, Taylor & Francis

    Ph.D. Toshinobu Hayashi

  2. Adrenaline-resistant anaphylactic shock caused by contrast medium in a patient after risperidone overdose: a case report

    Article • Journal of Pharmaceutical Health Care and Sciences, July 2023, Springer Science + Business Media

    Ph.D. Toshinobu Hayashi

  3. Chemotherapy-induced neutropenia as a prognostic factor in patients with extensive-stage small cell lung cancer

    Article • European Journal of Clinical Pharmacology, January 2023, Springer Science + Business Media

    Ph.D. Toshinobu Hayashi

  4. Effectiveness of Palonosetron, 1-Day Dexamethasone, and Aprepitant in Patients Undergoing Carboplatin-Based Chemotherapy

    Article • Oncology, January 2023, Karger Publishers

    Ph.D. Toshinobu Hayashi

  5. Combination Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients with NSCLC Receiving Carboplatin-Based Chemotherapy

    Article • Cancer Management and Research, September 2022, Taylor & Francis

    Ph.D. Toshinobu Hayashi

  6. Therapeutic effect of anti-HMGB1 antibody in a mouse model of 4-h middle cerebral artery occlusion: comparison with tissue plasminogen activator

    Article • Neuroreport, April 2022, Wolters Kluwer Health

    Ph.D. Toshinobu Hayashi

  7. Assisted Living and Medication Adherence in Super-aged Patients With Heart Failure in the Japanese Population

    Article • Journal of Cardiovascular Pharmacology, April 2022, Wolters Kluwer Health

    Ph.D. Toshinobu Hayashi

  8. Study protocol for a double-blind, comparative, randomised Japanese trial of triplet standard antiemetic therapies with or without 5 mg olanzapine to prevent chemotherapy-induced nausea and vomiting for patients with breast cancer treated with an anthr...

    Article • BMJ Open, March 2022, BMJ

    Ph.D. Toshinobu Hayashi

  9. Preventive effect of 20 mEq and 8 mEq magnesium supplementation on cisplatin-induced nephrotoxicity: a propensity score–matched analysis

    Article • Supportive Care in Cancer, January 2022, Springer Science + Business Media

    Ph.D. Toshinobu Hayashi

  10. Pooled analysis of combination antiemetic therapy for chemotherapy-induced nausea and vomiting in patients with colorectal cancer treated with oxaliplatin-based chemotherapy of moderate emetic risk

    Article • BMC Cancer, October 2021, Springer Science + Business Media

    Ph.D. Toshinobu Hayashi

  11. Efficacy of one-day versus multiple-day dexamethasone for chemotherapy-induced nausea and vomiting in lung cancer patients receiving carboplatin-based chemotherapy: a propensity score–matched analysis

    Article • Supportive Care in Cancer, February 2021, Springer Science + Business Media

    Ph.D. Toshinobu Hayashi

  12. Effects of Recommended Consultation Practice Using Fracture Risk Assessment Tool and Fracture Evaluation Questionnaire for Early Detection of Osteoporosis at Community Pharmacies

    Article • YAKUGAKU ZASSHI, February 2021, Pharmaceutical Society of Japan

    Ph.D. Toshinobu Hayashi

  13. Chemotherapy-induced nausea and vomiting (CINV) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: a propensity score-matched analysis

    Article • BMC Cancer, January 2021, Springer Science + Business Media

    Ph.D. Toshinobu Hayashi

  14. 5HT 3 RA plus dexamethasone plus aprepitant for controlling delayed chemotherapy‐induced nausea and vomiting in colorectal cancer

    Article • Cancer Science, December 2020, Wiley

    Ph.D. Toshinobu Hayashi

  15. 5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study

    Article • BMC Pharmacology and Toxicology, October 2020, Springer Science + Business Media

    Ph.D. Toshinobu Hayashi

  16. Effect of lubiprostone on vinca alkaloid–induced constipation in patients with hematological malignancies: a propensity score–matched analysis

    Article • Annals of Hematology, August 2020, Springer Science + Business Media

    Ph.D. Toshinobu Hayashi

  17. Antithrombin gamma attenuates macrophage/microglial activation and brain damage after transient focal cerebral ischemia in mice

    Article • Life Sciences, July 2020, Elsevier

    Ph.D. Toshinobu Hayashi

  18. Influence of proton pump inhibitors and H2-receptor antagonists on the efficacy and safety of dasatinib in chronic myeloid leukemia patients

    Article • International Journal of Hematology, March 2020, Springer Science + Business Media

    Ph.D. Toshinobu Hayashi

  19. Evaluation of the Collaboration between Community Interprofessionals and Pharmacists for Early Detection of Dementia

    Article • YAKUGAKU ZASSHI, December 2019, Pharmaceutical Society of Japan

    Ph.D. Toshinobu Hayashi

  20. A Nationwide, Multicenter Registry Study of Antiemesis for Carboplatin-Based Chemotherapy-Induced Nausea and Vomiting in Japan

    Article • The Oncologist, October 2019, Oxford University Press (OUP)

    Ph.D. Toshinobu Hayashi

  21. Evaluation of Combination Antiemetic Therapy on CINV in Patients With Gynecologic Cancer Receiving TC Chemotherapy

    Article • Anticancer Research, December 2018, International Institute of Anticancer Research

    Ph.D. Toshinobu Hayashi

  22. Risk factors for delayed chemotherapy-induced nausea and vomiting with low-emetic-risk chemotherapy: a prospective, observational, multicenter study

    Article • Cancer Management and Research, October 2018, Dove Medical Press

    Ph.D. Toshinobu Hayashi

  23. Genetic risk factors for chemotherapy-induced nausea and vomiting in patients with cancer receiving cisplatin-based chemotherapy

    Article • Supportive Care in Cancer, November 2017, Springer Science + Business Media

    Keita Hirai, Ph.D. Toshinobu Hayashi

  24. Involvement of Charcot-Marie-Tooth disease gene mitofusin 2 expression in paclitaxel-induced mechanical allodynia in rats

    Article • Neuroscience Letters, July 2017, Elsevier

    Ph.D. Toshinobu Hayashi

  25. Comprehensive study of risk factors for chemotherapy-induced nausea and vomiting in cancer patients receiving cisplatin-based chemotherapy: A TRIPLE pharmacogenomics study.

    Article • Journal of Clinical Oncology, May 2017, American Society of Clinical Oncology (ASCO)

    Keita Hirai, Ph.D. Toshinobu Hayashi

  26. A prospective, observational, multicenter study on risk factors and prophylaxis for low emetic risk chemotherapy-induced nausea and vomiting

    Article • Supportive Care in Cancer, March 2017, Springer Science + Business Media

    Ph.D. Toshinobu Hayashi

  27. P3.05-007 Prospective Evaluation for Combination Antiemetic Therapy on CINV in NSCLC Receiving Carboplatin-Based Chemotherapy of MEC

    Article • Journal of Thoracic Oncology, January 2017, Elsevier

    Ph.D. Toshinobu Hayashi

  28. Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study

    Article • Annals of Oncology, August 2016, Elsevier

    Ph.D. Toshinobu Hayashi

  29. Influence of ABCB1 and ABCG2 polymorphisms on the antiemetic efficacy in patients with cancer receiving cisplatin-based chemotherapy: a TRIPLE pharmacogenomics study

    Article • The Pharmacogenomics Journal, May 2016, Nature

    Keita Hirai, Ph.D. Toshinobu Hayashi

  30. Factors associated with effects of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory low-grade B cell non-Hodgkin lymphoma: single-institution experience with 94 Japanese patients in rituximab era

    Article • International Journal of Hematology, August 2014, Springer Science + Business Media

    Ph.D. Toshinobu Hayashi

  31. Efficacy and safety of yttrium-90 ibritumomab tiuxetan in Japanese patients with non-Hodgkin lymphoma

    Article • Japanese Journal of Radiology, July 2012, Springer Science + Business Media

    Ph.D. Toshinobu Hayashi

  32. Implementation of institutional antiemetic guidelines for low emetic risk chemotherapy with docetaxel: a clinical and cost evaluation

    Article • Supportive Care in Cancer, September 2011, Springer Science + Business Media

    Ph.D. Toshinobu Hayashi

  33. Vaccination with dendritic cells pulsed with apoptotic cells elicits effective antitumor immunity in murine hepatoma models

    Article • International Journal of Oncology, May 2005, Spandidos Publications

    Ph.D. Toshinobu Hayashi